目的 初步探讨生长激素释放激素受体（GHRHR）在肾上腺肿瘤组织中的表达及其在临床中的实际应用价值。 方法 应用免疫组织化学方法检测2001年1月－2009年10月间187例肾上腺肿瘤和20例正常肾上腺组织标本中GHRHR的表达。 结果 肾上腺皮质肿瘤与肾上腺髓质肿瘤、正常肾上腺组织比较，GHRHR表达明显增高（阳性率分别为99%、45%、55%），GHRHR在肾上腺皮质醇瘤和醛固酮瘤中表达的差异有统计学意义，在肾上腺皮质腺瘤、皮质腺癌、皮质增生中表达的差异有统计学意义。 结论 GHRHR在人正常肾上腺及肾上腺肿瘤组织中的表达，为在垂体外组织及人类肿瘤组织存在GHRHR的表达提供了直接证据；GHRHR可能会用于肾上腺皮质肿瘤和髓质肿瘤的鉴别诊断，但GHRHR尚不能用于良性和恶性肾上腺皮质肿瘤的鉴别诊断。GHRHR在肾上腺皮质相关肿瘤的高表达，可能与肾上腺皮质肿瘤的发病机制有关。
目的 研究尿标本中防腐剂盐酸对24 h尿游离皮质醇测定的影响。 方法 收集2008年7月-2009年1月正常人、库欣病患者及其他疾病患者的24 h尿液，混匀后，一部分浓盐酸防腐，一部分未加盐酸直接保存。电化学发光免疫分析法同步检测尿游离皮质醇浓度。 结果 经配对 t 检验加浓盐酸后的24 h尿游离皮质醇测值均高于未加酸者，比较有统计学意义（Plt;0.05）。加盐酸和未加盐酸所测尿游离皮质醇二者之间具有较好的相关性，相关系数 r =0.97，P lt;0.05。 结论 浓盐酸防腐的标本24 h尿游离皮质醇测值较未加酸保存的标本高。因此，为了得到相对准确的值，更好地反映肾上腺实际分泌情况，测定24 h尿游离皮质醇的标本不应使用盐酸防腐。
目的:评价免疫印迹法检测胰岛自身抗体（GAD-A、ICA、IAA）与酶联免疫法测ICA、GAD-A放射免疫法测IAA结果的一致性。方法:采用免疫印迹法测定81例糖尿病患者胰岛自身抗体,将结果与酶联免疫法测定的GAD-A、ICA,放射免疫法测定IAA结果进行比较。结果:免疫印迹法阳性检出率为:GAD-A 51.8%,ICA 18.5%,IAA 27.1%；酶联免疫法（GAD-A、ICA）、放射免疫法（IAA）阳性检出率:GAD-A 32.1%,ICA 34.5%,IAA 30.8%；上述两组结果进行比较,两组相比ICA和GAD-A有统计学差异（Plt;0.05）,IAA无统计学差异。两组结果一致率比较:GAD-A 50.6%,ICA 64.2%,IAA 69.1%。结论:与临床常用酶联免疫法检测GAD-A、ICA,放射免疫法检测IAA比较,免疫印迹法和酶联免疫法在ICA及GAD-A阳性检出率上的差异有显著性,和放射免疫法在IAA阳性检出率上差异无显著性。
Objective To evaluate the safety and efficacy of venlafaxine and carbamazepine on painful peripheral diabetic neuropathy. Methods This was a randomized, parallel-group, double-blind, double-dummy clinical trial. 132 patients a venlafaxine group (n=66) and a carbamazepine group (n=66) with painful peripheral diabetic neuropathy were recruited from 3 clinical centers. The venlafaxine group took venlafaxine 25 mg plus one dummy carbamazepine tablet twice a day and the carbamazepine group took carbamazepine 0.1 g plus one dummy venlafaxine tablet twice a day both for 2 weeks. The primary efficacy measurement consisted of a numeric pain intensity scale and the secondary measurement assessed quality of life. Results One hundred and nineteen patients completed the trial. Venlafaxine was superior to carbamazepine in improving mean pain intensity scores at 5,7,10 and 14 days by per-protocol analysis (P=0.02, P=0.03, P=0.003 and P=0.001 respectively). The effects of venlafaxine on the improvement in the total quality of life scores were better than those of carbamazepine at 10 and 14 days (P=0.02 and P=0.01 respectively). Sleep interference and mood were improved by both venlafaxine and carbamazepine, but the efficacy of venlafaxine was superior to that of carbamazepine. The common adverse events of venlafaxine included mild gastrointestinal discomfort, dizziness and somnolence. The frequency of adverse events in the venlafaxine group was about 43.9% (4 patients withdrew because of adverse events) and in the carbamazepine group about 25.76% (2 patients withdrew because of adverse events) (P =0.06). Conclusions Venlafaxine and carbamazepine are effective in the treatment of painful diabetic neuropathy, venlafaxine is superior to carbamazepine in improving pain and quality of life. Both drugs may be safe and well tolerated.